According to the latest research report the
transarterial
chemoembolization (TACE) market size is projected to reach USD 15.61
Billion by 2030 at 4.90% CAGR during the forecast period 2022-2030.
Hepatocellular carcinoma (HCC) is a primary
malignancy of the liver and occurs mainly due to chronic liver disease and
cirrhosis. It is the third leading cause of cancer deaths worldwide, with over
500,000 people affected. Transarterial chemoembolization market is the
current standard of therapy for patients with intermediate-stage hepatocellular
carcinoma (HCC). Conventional TACE is considered as a standard treatment for
HCC.
Key Players
- Advaxis Inc. (US)
- Baxter (US)
- Bellicum Pharmaceuticals, Inc. (US)
- Boston Scientific Corporation (US)
- Cook (US)
- Hikma Pharmaceuticals PLC (UK)
- Isofol Medical AB (Sweden)
- Nippon Kayaku Co., Ltd. (Japan)
- Novartis (Switzerland)
- Pfizer (US)
- Sirtex SIR-Spheres Pty Ltd. (Australia)
- Spectrum Pharmaceuticals, Inc. (US)
- Jiangsu Hengrui Medicine Co., Ltd (China)
Segmentation
By Procedure Type
- Conventional TACE: Conventional
TACE dominated the Transarterial
chemoembolization (TACE) market insights as it is one of the oldest
procedures used in HCC cases. Conventional TACE involves the infusion
of chemotherapeutic drugs blended with lipiodol and embolic agents into
the cancer-feeding artery and liver cancer transarterial chemoembolization
- DEB-TACE: This segment is expected
to witness the fastest growth. DEB-TACE allows higher concentrations
of drugs to the target tumor and lower systemic concentrations, compared
with conventional TACE
By Product Type
- Chemotherapeutic Agents: Held
the largest market share in 2018. Doxorubicin, cisplatin, and mitomycin
are most commonly used in the TACE procedure. Doxorubicin is the most
widely used chemotherapeutic agent for TACE of HCC. The dose of
doxorubicin generally ranges from 30 to 75 mg/m2
- Radiotherapeutic Agents: TACE with
radiotherapeutic agents is the most expensive treatment for liver tumors.
- Drug-eluting Particles: Drug-eluting
beads have been imposed as novel drug-delivering agents for TACE. DC Beads
is one of the most commonly used Drug-eluting beads. These beads are
nonbiodegradable PVA microspheres, loaded with calibrated doxorubicin
By End-User
- Hospitals & Clinics: It holds
the largest market share that can be attributed to an increase in the
number of patients afflicted by HCC, coupled with a rise in a number of
hospitals, and quality care, and availability of skilled and qualified
professionals.
- Cancer Research Centers: This is
the fastest-growing segment due to increasing research funding for the
development of effective treatment of HCC
By Region
- Americas: The region holds the
largest share of the market. The market in the Americas has further been branched
into North America and Latin America, with the North American market
divided into the US and Canada.
- Europe: The European
transarterial chemoembolization (TACE) market has been classified as
Western Europe and Eastern Europe. The Western European market has further
been categorized as Germany, France, the UK, Italy, Spain, and the rest of
Western Europe.
- Asia-Pacific: The market in
Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. The Asia-Pacific transarterial
chemoembolization (TACE) market is projected to be the fastest-growing
during the forecast period.
- Middle East & Africa: The
market in the Middle East & Africa has been divided into the Middle
East and Africa.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
The Wall